

IQNovate unanimously approved by the GXG Admissions Committee, to commence trading on the Main Quote of GXG.

IQNovate Ltd will now be trading on the European stock exchange for SME's

SYDNEY, Australia, September 12, 2013 - IQNovate limited (NSX: IQN, OTC: IQNDY, GXG: IQN), a life science organization providing intellectual property asset management and scientific advice to the global biopharmaceutical industry, announced today that it was unanimously approved to list, by the GXG Admissions Committee, on the 10th of September.

The Company has been admitted to the Main Quote of the GXG Markets with an opening price of 0.822 EUR, giving it a market capitalization of 30,788,741.58 EUR, using its current quote on NSX.

George Syrmalis CEO and Chairman of IQNovate Ltd commented "IQNovate shares are now traded in 3 continents, 24 hrs/day and exposed to hundreds of millions of potential investors. IQNovate has now created a solid multinational shareholder infrastructure, enabling it to execute its global M&A strategy".

Con Tsigounis, Investor Relations. Telephone: +61 (2) 8239-5400

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQNovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE IQNovate Limited

IQNovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, IQNovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

IQNovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.